A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice

Tang, Jun; Yin, Rui; Tian, Yi; Huang, Zeming; Shi, Jinglei; Fu, Xiaolan; Wang, Li; Wu, Yuzhang; Fei, Hao; Ni, Bing

doi:10.1016/j.vaccine.2011.12.029

Cited by 51 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, formulation of antigens into particles provides some protection against enzymatic degradation, which is important for highly susceptible peptide antigens. Noticeably, in contrast to many previously reported peptide-based vaccine candidates, 33,46,47,58 S4-8Q min demonstrated a therapeutic effect after a single immunization.…”

Section: Resultscontrasting

confidence: 82%

See 1 more Smart Citation

Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer

et al. 2013

View full text Add to dashboard Cite

Dendrimers are structurally well-defined, synthetic polymers with sizes and physicochemical properties often resembling those of biomacromolecules (e.g. proteins). As a result they are promising candidates for peptide-based vaccine delivery platforms. Herein, we established a synthetic pathway to conjugate a human papillomavirus (HPV) E7 protein-derived peptide antigen to a star-polymer to create a macromolecular vaccine candidate to treat HPV-related cancers. These conjugates were able to reduce tumor growth and eradicate E7-expressing TC-1 tumors in mice after a single immunization, without the help of any external adjuvant.

show abstract

Section: Resultscontrasting

confidence: 82%

“…(QAEPDRAHYNIVTFCCKCD; E7 [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] ) which contains a CTL epitope (CD8 + cytotoxic T lymphocytes), and T-helper cell (CD4 + ) and B-cell epitopes ( Figure 1). 9 This combination makes 8Q an ideal candidate to stimulate long-term vaccine efficacy to kill cancer cells.…”

mentioning

confidence: 99%

Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These series of observations demonstrate that the ZEBRA-derived CPP-linked to antigenic cargo is a very powerful system able to break self-tolerance and to induce therapeutic anti-tumor immune responses in vivo. Increased Ag-specific immune responses have also been reported by linking other tumor Ag to a CPP, such as TRP2 [25–27], carcinoembryonic antigen (CEA) [28], p53 [29], survivin [30], MUC-1 [31], HPV16 E7 [23], or HER2/neu [32]. Moreover, vaccination with these constructs induced either prophylactic or therapeutic anti-tumor effects in vivo.…”

Section: Cpps Coupled To Antigenic Cargos and Their Application To Camentioning

confidence: 99%

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines

Grau¹,

Walker

Derouazi³

2018

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Immunotherapies are increasingly used to treat cancer, with some outstanding results. Immunotherapy modalities include therapeutic vaccination to eliminate cancer cells through the activation of patient’s immune system against tumor-derived antigens. Nevertheless, the full potential of therapeutic vaccination has yet to be demonstrated clinically because many early generation vaccines elicited low-level immune responses targeting only few tumor antigens. Cell penetrating peptides (CPPs) are highly promising tools to advance the field towards clinical success. CPPs efficiently penetrate cell membranes, even when linked to antigenic cargos, which can induce both CD8 and CD4 T-cell responses. Pre-clinical studies demonstrated that targeting multiple tumor antigens, even those considered to be poorly immunogenic, led to tumor regression. Therefore, CPP-based cancer vaccines represent a flexible and powerful means to extend therapeutic vaccination to many cancer indications. Here, we review recent findings in CPP development and discuss their use in next generation immunotherapies.

show abstract

“…On day 4 post-vaccination, splenocytes were incubated with 1 g/ml Ova 257 peptide for 6 h and subsequently performed for intracellular IFN-␥ staining using ␣CD8 and ␣CD45.2 Abs. In vivo cytotoxicity assay was performed as described previously [14]. Mice were euthanized 20 h later, and the ratio of CFSE high to CFSE low cells in splenocytes was determined.…”

Section: In Vitro In Vivo Proliferation and Cytotoxicity Assaysmentioning

confidence: 99%

CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects

Park

Sohn

Kim

et al. 2014

Vaccine

View full text Add to dashboard Cite

A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice

Cited by 51 publications

References 30 publications

Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer

Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines

CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects

Contact Info

Product

Resources

About